CCDC97: A Protein Implicated in Neurodegenerative Diseases and Tumors
CCDC97: A Protein Implicated in Neurodegenerative Diseases and Tumors
CCDC97 (MGC20255) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the T-cell transition factor (T-TF) family, which is a subgroup of the transcription factor family. Members of the T-TF family play important roles in regulating various physiological processes such as cell cycle, proliferation, differentiation, and apoptosis. CCDC97 is expressed in a variety of cancers, including neuroblastoma, breast cancer, lung cancer, and colon cancer. In addition, CCDC97 has been associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Alzheimer's disease.
The crystal structure of CCDC97 was solved in 2016. It consists of two domains: N-terminal 伪-helix, mid-尾-sheet and C-terminal 尾-helix. The N-terminal 伪-helix is 鈥嬧?媜ne of the most striking features of the CCDC97 structure. It is composed of three consecutive 伪-helices, surrounded by a bright 伪-helix stacking region and a dark 尾-sheet band in the middle. The C-terminal 尾-helix is 鈥嬧?媍omposed of two complementary 尾-helices that are closely packed together in space.
Functional studies of CCDC97 have mainly focused on its relationship with neurodegenerative diseases. Neurodegenerative diseases are a type of neurological diseases caused by the damage or death of nerve cells, including Parkinson's disease, Alzheimer's disease and Alzheimer's disease. These diseases can lead to neuronal apoptosis, increase the number of neuronal synapses, aggravate neuronal damage, and ultimately lead to neuronal death.
Neuronal apoptosis is an important factor in patients with Parkinson's disease. Studies have shown that the number of neuronal apoptosis in the brains of Parkinson's disease patients is many times higher than that of normal people. Moreover, CCDC97 is closely related to neuronal apoptosis. Researchers found that the activity of CCDC97 in the brains of Parkinson's disease patients was significantly higher than that of normal people. In addition, the number of neuron synapses in the brains of patients with Parkinson's disease is also increased compared with normal people. These findings suggest that CCDC97 may be closely related to the development of Parkinson's disease.
In addition to its relationship with neurodegenerative diseases, CCDC97 is also closely related to tumor initiation and progression. Studies have shown that the expression level of CCDC97 is related to the invasiveness and metastasis of various tumors. For example, in breast cancer, the expression level of CCDC97 is high and is positively correlated with the invasiveness and metastasis of breast cancer.
In addition, CCDC97 is also related to the survival and proliferation of neurons. Studies have shown that CCDC97 can inhibit neuronal apoptosis and increase neuronal survival time and proliferation. These findings suggest that CCDC97 may play a role in diseases related to neuronal survival and proliferation.
In summary, CCDC97 is a protein that plays an important role in the occurrence and development of neurodegenerative diseases and tumors. Its functional studies are of great significance for a deeper understanding of the mechanisms of neurodegenerative diseases, tumor initiation and progression, and neuronal survival and proliferation. Therefore, CCDC97 may be a potential drug target or biomarker.
Protein Name: Coiled-coil Domain Containing 97
The "CCDC97 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC97 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCDC9B | CCDST | CCEPR | CCER1 | CCER2 | CCHCR1 | CCIN | CCK | CCK receptor | CCKAR | CCKBR | CCL1 | CCL11 | CCL13 | CCL14 | CCL15 | CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7
